A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

Sponsor
Pfizer
Study ID
NCT07497854
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Migraine With or Without Aura

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).

Key Dates

Start date
Oct 1, 2026
Status verified
Mar 2026
Primary completion
Jul 31, 2030
Completion
Aug 1, 2030

Study Design

Enrollment
3,000 participants (estimated)

Arms

  • Arm: Rimegepant sulfate

Primary Outcome Measure

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. [ Time Frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) ]

Central Contacts